Skip to content
10-Q

Quarterly Report

REGENERX BIOPHARMACEUTICALS, INC.

0001104659-21-066826

← back to feed
Filed
May 14, 2021 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2021 · May 7, 2021 133.55M sh
Cash And Equivalents Q1 2021 · Mar 31, 2021 $207.61K
Cash And Equivalents Q1 2021 · Dec 31, 2020 $427.9K
Current Liabilities Q1 2021 · Mar 31, 2021 $431.75K
Current Liabilities Q1 2021 · Dec 31, 2020 $399.58K
Total Liabilities Q1 2021 · Mar 31, 2021 $3.44M
Total Liabilities Q1 2021 · Dec 31, 2020 $3.38M
Current Assets Q1 2021 · Mar 31, 2021 $250.86K
Current Assets Q1 2021 · Dec 31, 2020 $477.81K
Total Assets Q1 2021 · Mar 31, 2021 $315.44K
Total Assets Q1 2021 · Dec 31, 2020 $551.79K
Shares Diluted Q1 2021 · Mar 31, 2020 133.1M sh
Operating Cash Flow Q1 2021 · Mar 31, 2020 −$267.05K
Stockholders Equity Q1 2021 · Mar 31, 2020 −$2.44M
Stockholders Equity Q1 2021 · Dec 31, 2019 −$2.34M
Eps Diluted Q1 2021 · Mar 31, 2020 $0.00
Eps Basic Q1 2021 · Mar 31, 2020 $0.00
Sga Expense restated Q1 2021 · Mar 31, 2020 $356.86K
Rd Expense restated Q1 2021 · Mar 31, 2020 $475
Net Income Q1 2021 · Mar 31, 2020 −$386.73K
Operating Income Q1 2021 · Mar 31, 2020 −$338.15K
Revenue Q1 2021 · Mar 31, 2020 $19.19K